German Health Data Providers Compared: Claims Data Access, GDNG Compliance and RWE Fit for Pharma Research
Germany has one of the most analytically valuable health data environments in Europe — and one of the most structurally
Outcome Prediction Models in Healthcare: Using RWD to Build Predictive Analytics
Here’s the version of predictive modelling in pharma that doesn’t get discussed enough in vendor conversations: the one where the
Outcome Prediction Models in Healthcare: Using RWD to Build Predictive Analytics Read Post »
Longitudinal Data Analysis in Pharma: What Makes a Dataset Fit for Purpose
Here’s a pattern we see repeatedly in the RWE programmes we advise on across Continental European markets: a company selects
Longitudinal Data Analysis in Pharma: What Makes a Dataset Fit for Purpose Read Post »
Phenotype Validation in Claims Data: The RWE Step That Determines Whether Your Study Stands or Falls
Here’s something we see consistently in the RWE programmes we advise on: teams invest months in study design, data access
RWE FDA Regulatory Submission Guide: What FDA and EMA Now Accept as Real-World Evidence for Drug Approval and Label Expansion
In December 2025, the FDA announced it was eliminating a major barrier to using real-world evidence in drug and device
Rare Disease RWE Strategy: Synthetic Control Arms, Natural History Studies and Real-World Evidence for Orphan Drug Development
Here’s a conversation I’ve had more times than I can count. A clinical development director at a rare disease biotech
Real-World Evidence Myths: 5 Things Pharma Teams Get Wrong About RWE, Claims Data and Study Design
Every year, pharma companies spend tens of millions of dollars on real-world evidence programmes that fail to deliver what was
Why Pharma Launches Fail: How Real-World Data Exposes the Market Sizing, Patient Journey and Payer Uptake Gaps Behind Failed Drug Launches
Here’s a number that should make any launch team uncomfortable: more than half of all pharma launches miss their commercial